<DOC>
	<DOCNO>NCT00316264</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind study motavizumab ( MEDI-524 ) palivizumab administer sequentially high-risk child respiratory syncytial virus ( RSV ) season . A control group administer motavizumab .</brief_summary>
	<brief_title>Study Motavizumab ( MEDI-524 ) Palivizumab Administered Sequentially Same Respiratory Syncytial Virus ( RSV ) Season</brief_title>
	<detailed_description>This Phase 2 , randomize , double-blind study motavizumab palivizumab administer sequentially high-risk child RSV season . It anticipate approximately 240 child ( 80 group ) would enrol southern hemisphere upcoming RSV season ( 2006 ) . Children randomize one three regimens 1:1:1 ratio ; first group receive 2 dos motavizumab follow 3 dos palivizumab ; second group receive 2 dos palivizumab follow 3 dos motavizumab ; third group receive 5 dos motavizumab . Motavizumab palivizumab administer 15 mg/kg IM injection every 30 day , total 5 injection .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>The child must bear less equal 35 week gestation less equal 6 month age time entry study ( child must enter his/her 6month birthday ) ; child must less equal 24 month age time entry study ( child must enter his/her 24month birthday ) diagnose chronic lung disease ( CLD ) prematurity stable decreasing dos diuretic , steroid , bronchodilator , treatment supplemental oxygen , within previous 6 month . The child must general good health time study entry . The child 's parent ( ) /legal guardian must provide write informed consent . The child must able complete followup visit 120150 day last injection study drug . Parent ( ) /legal guardian patient must available telephone access . Hospitalized time study entry ( unless discharge expect within 10 day entry study ) Receiving chronic oxygen therapy mechanical ventilation time study entry ( include continuous positive airway pressure [ CPAP ] ) Congenital heart disease ( CHD ) ( child medically surgically correct [ close ] patent ductus arteriosus CHD may enrol ) Evidence infection hepatitis A , B , C virus Known renal impairment , hepatic dysfunction , chronic seizure disorder , immunodeficiency HIV infection ( child mother know HIV infection must prove uninfected time enrollment ) Suspected serious allergic immunemediated event prior receipt palivizumab Acute illness progressive clinical disorder Active infection , include acute RSV infection , time enrollment Previous reaction intravenous immunoglobulin ( IGIV ) , blood product , foreign protein Received within past 120 day currently receive immunoglobulin product ( RSVIGIV [ RespiGam ] , IVIG , palivizumab ) investigational agent Previous participation clinical trial motavizumab Currently participate investigational study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Respiratory Syncytial Virus</keyword>
	<keyword>Premature 6 mo . age</keyword>
	<keyword>Chronic Lung Disease 6 mo . age</keyword>
	<keyword>palivizumab</keyword>
	<keyword>motavizumab</keyword>
	<keyword>RSV</keyword>
</DOC>